This is a randomized, double-blind, placebo- controlled, single and multiple dosing, dose-escalation clinical phase 1 trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of NXC736 after oral administration in healthy male volunteers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Enrollment
72
Seoul National University Hospital
Seoul, South Korea
Number of Participants with Adverse Events (AEs)
Time frame: Day 49
Number of Participants with Serious Adverse Events (SAEs)
Time frame: Day 49
Number of Participants with Vital Sign Abnormalities
Time frame: Day 49
Number of Participants with Electrocardiogram (ECG) Abnormalities
Time frame: Day 49
Number of Participants with Clinical Laboratory Abnormalities
Time frame: Day 49
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.